3-AP and Gemcitabine in Treating Patients With Unresectable or Metastatic Pancreatic Cancer

Completed · Phase 2

Conditions studied: Pancreatic Cancer

In brief

RATIONALE: Drugs used in chemotherapy such as gemcitabine use different ways to stop tumor cells from dividing so they stop growing or die. 3-AP may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth and may help gemcitabine kill more cancer cells by making them more sensitive to the drug. PURPOSE: This phase II trial is studying how well giving gemcitabine together with 3-AP works in treating patients with unresectable or metastatic pancreatic cancer.

Key facts

Study ID

NCT00064051

Run by

Vion Pharmaceuticals

Starts

2003-01-01

Expected to finish

2008-08-01

Last updated by the study team

2013-08-02

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• University of Chicago Cancer Research Center — Chicago, Illinois, United States
• Indiana Oncology Hematology Consultants — Indianapolis, Indiana, United States
• University of Minnesota Cancer Center — Minneapolis, Minnesota, United States
• Sarah Cannon Cancer Center at Centennial Medical Center — Nashville, Tennessee, United States
• Universitair Ziekenhuis Gent — Ghent, Belgium
• Christie Hospital N.H.S. Trust — Manchester, England, United Kingdom
• Royal Marsden NHS Foundation Trust - Surrey — Sutton, England, United Kingdom

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.